Genomics in Cardiovascular Diseases
No Cover

Genomics in Cardiovascular Diseases

For Researchers and Cardiologists

Dr A M Thirugnanam

From the genetic test report to the treatment decision, this is the clinical genomics reference cardiologists have been waiting for.

A genetic report lands on your desk: a MYBPC3 VUS, a TTN truncating variant, a CYP2C19 poor-metaboliser result. Knowing what it means, and what to do next for the patient and the whole family, is now a core cardiology skill.

Genomics in Cardiovascular Diseases is a 16-chapter international reference by Dr A M Thirugnanam, a senior interventional cardiologist and medical educator. It turns cardiovascular genomics into practical, guideline-anchored decisions.

Interpreting the genome
• Decoding the genetic test report: ACMG/AMP evidence criteria, ClinGen refinements, ClinVar and gnomAD
• Variants of uncertain significance: a structured 5-step reclassification workflow, co-segregation, functional evidence and medicolegal duties
• Whole exome and whole genome sequencing in undiagnosed cardiomyopathy: diagnostic yield, secondary findings (ACMG SF v3.2) and reanalysis

Inherited cardiovascular disease
• HCM and DCM: sarcomere genes, titin truncating variants, LMNA, HCM Risk-SCD, and cardiac myosin inhibitors (EXPLORER-HCM, VALOR-HCM)
• Arrhythmogenic cardiomyopathy: PKP2, left-dominant DSP disease, Task Force criteria and exercise restriction
• Channelopathies: gene-specific algorithms for LQTS, Brugada syndrome and CPVT
• Familial hypercholesterolaemia: DLCN criteria, monogenic vs polygenic FH, PCSK9 inhibitors (FOURIER, ODYSSEY OUTCOMES), inclisiran (ORION) and evinacumab
• Heritable aortopathies: Marfan (Ghent), Loeys-Dietz, ACTA2 and vascular EDS, with gene-specific surgical thresholds
• Sudden cardiac death: molecular autopsy, reporting standards and family surveillance

Precision cardiology in practice
• Pharmacogenomics at the bedside: CYP2C19 and P2Y12 inhibitors (TAILOR-PCI, POPular Genetics), VKORC1/CYP2C9 and warfarin (COAG, EU-PACT), SLCO1B1 and statins, with CPIC guidance
• Cascade screening workflows and multi-generational risk communication
• Polygenic risk scores for CAD and AF, validated in UK Biobank
• Multi-omics: transcriptomics, epigenomics and proteomics in heart failure
• Building and running the cardio-genomics MDT
• Gene and RNA therapies: CRISPR and base editing (NTLA-2001, VERVE-101), and ATTR silencers (HELIOS-B)
• Ethics, consent, GINA and the duty to warn

Every chapter includes learning objectives, comparison tables, clinical case vignettes, key clinical pearls and current references. Board-style MCQs feature in selected chapters.

Ideal for interventional and clinical cardiologists, electrophysiologists, cardiology fellows, genetic counsellors, and translational researchers in cardiovascular genomics.

Book Info

Publisher Academy of Elite Doctors
Release Date 2026-06-14
Page Count 483 Pages
File Size 3.3 MB
Language en-US

No download link available yet. You can .

Related Books

Similar recommendations you might enjoy

Join Telegram